235 related articles for article (PubMed ID: 31757838)
1. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.
Bethel MA; Mentz RJ; Merrill P; Buse JB; Chan JC; Goodman SG; Iqbal N; Jakuboniene N; Katona B; Lokhnygina Y; Lopes RD; Maggioni AP; Ohman P; Tankova T; Bakris GL; Hernandez AF; Holman RR
Diabetes Care; 2020 Feb; 43(2):446-452. PubMed ID: 31757838
[TBL] [Abstract][Full Text] [Related]
2. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
3. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
4. Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Reed SD; Li Y; Dakin HA; Becker F; Leal J; Gustavson SM; Kartman B; Wittbrodt E; Mentz RJ; Pagidipati NJ; Bethel MA; Gray AM; Holman RR; Hernandez AF;
Diabetes Care; 2020 Feb; 43(2):374-381. PubMed ID: 31806653
[TBL] [Abstract][Full Text] [Related]
5. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
6. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
7. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
van der Aart-van der Beek AB; Clegg LE; Penland RC; Boulton DW; Sjöström CD; Mentz RJ; Holman RR; Heerspink HJL
Diabetes Obes Metab; 2020 Dec; 22(12):2493-2498. PubMed ID: 32803900
[TBL] [Abstract][Full Text] [Related]
8. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial.
Badjatiya A; Merrill P; Buse JB; Goodman SG; Katona B; Iqbal N; Pagidipati NJ; Sattar N; Holman RR; Hernandez AF; Mentz RJ; Patel MR; Jones WS
Circ Cardiovasc Interv; 2019 Dec; 12(12):e008018. PubMed ID: 31752517
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.
Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Desai M; Li Q; Deng H; Rosenthal N; Jardine MJ; Bakris G; Perkovic V
Circulation; 2018 Oct; 138(15):1537-1550. PubMed ID: 29941478
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Green JB; Merrill P; Lokhnygina Y; Mentz RJ; Alfredsson J; Holman RR;
Diabetes Obes Metab; 2023 Jun; 25(6):1473-1484. PubMed ID: 36700460
[TBL] [Abstract][Full Text] [Related]
12. Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.
Mentz RJ; Bethel MA; Merrill P; Lokhnygina Y; Buse JB; Chan JC; Felício JS; Goodman SG; Choi J; Gustavson SM; Iqbal N; Lopes RD; Maggioni AP; Öhman P; Pagidipati NJ; Poulter NR; Ramachandran A; Reicher B; Holman RR; Hernandez AF;
J Am Heart Assoc; 2018 Oct; 7(19):e009304. PubMed ID: 30371301
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Mentz RJ; Bethel MA; Gustavson S; Thompson VP; Pagidipati NJ; Buse JB; Chan JC; Iqbal N; Maggioni AP; Marso SP; Ohman P; Poulter N; Ramachandran A; Zinman B; Hernandez AF; Holman RR
Am Heart J; 2017 May; 187():1-9. PubMed ID: 28454792
[TBL] [Abstract][Full Text] [Related]
14. Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Idzerda NMA; Clegg LE; Hernandez AF; Bakris G; Penland RC; Boulton DW; Bethel MA; Holman RR; Heerspink HJL
Diabetes Obes Metab; 2020 May; 22(5):798-806. PubMed ID: 31912603
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
16. Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
Davis TME; Giczewska A; Lokhnygina Y; Mentz RJ; Sattar N; Holman RR;
Cardiovasc Diabetol; 2022 Jun; 21(1):116. PubMed ID: 35761271
[TBL] [Abstract][Full Text] [Related]
17. Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Mann JFE; Fonseca V; Mosenzon O; Raz I; Goldman B; Idorn T; von Scholten BJ; Poulter NR
Circulation; 2018 Dec; 138(25):2908-2918. PubMed ID: 30566006
[TBL] [Abstract][Full Text] [Related]
18. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
[TBL] [Abstract][Full Text] [Related]
20. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
